On November 30, Louis Navellier Reveals Bold New Income Strategy

Need cash now? Then check out The One Percent Event on November 30 at 12 p.m. ET.

Wed, November 30 at 12:00PM ET

ABBV: AbbVie Beats Street on Soaring Humira Sales

On Friday, AbbVie (ABBV) reported higher quarterly earnings and revenues. ABBV stock rose more than 3% in morning trading.

abbvie ABBVABBV shares moved higher after the pharmaceutical-maker said it earned $980 million during the first quarter, up 1.2% from $968 million in the prior-year period. Adjusted EPS came in at 71 cents, beating guidance issued earlier this year, Reuters noted.

Quarterly sales climbed to $4.56 billion, up 5.4% over the year-ago period, and topping the $4.33 billion that Wall Street was expecting.

AbbVie said that its first quarter results were boosted by a 18% jump in worldwide sales of its rheumatoid arthritis drug, Humira, the Wall Street Journal noted. During the quarter, global Humira sales hit $2.6 billion.

On Thursday, AbbVie stock closed at $49.32 per share.

More Stocks in the News:

Article printed from InvestorPlace Media, https://investorplace.com/2014/04/abbv-abbvie-beats-street-soaring-humira-sales/.

©2022 InvestorPlace Media, LLC